All roads in the pharmaceutical markets across the world will lead to the land of rising sun, Japan, from July 1 to July 3 this year for the Asia's largest pharmaceutical industry event 'the 22nd Interphex Japan' where an estimated 63000 visitors will vie with each other at the around 1400 exhibition stalls to keep themselves abreast of the latest developments in the pharma industry. The event, which will be held at Tokyo Big Sight, will be a perfect platform to meet the Japanese pharma, biotech and allied companies to strike possible business deals.
Along with Interphex Japan, other events like international trade fair specialised for pharmaceutical/cosmetics ingredients 'Pharma i Japan', and Asia's largest bio event 'Int'l Bio Forum & Bio Expo Japan' will also be held at Tokyo Big Sight, Japan from July 1 to 3, 2009. At the venue, business meetings are enthusiastically held between professionals of pharmaceutical manufacturers and exhibitors from all over the world. Inside concurrently held "Technical Conference," a large number of sessions/seminars attract a large number of attendees as the best place for enhancing knowledge on the latest trends in the pharmaceutical industry.
The event this year is being held on the background of a big problem that is staring at Japan. The pharmaceutical industry in Japan is said to face severe problems in the year 2010. The main force drugs developed in the 1990's are expiring of patent. Since discovering new medicines takes 10-15 years of time with huge amount of development costs, pharmaceutical prices are influenced by the ratio of the costs of development fee.
In addition, since new drugs have the possibilities of setting back before available to consumers, pharmaceutical manufacturers are exerting themselves looking for new seeds and researching for new drugs. Up till now, Health, Labor and Welfare Ministry have protected the Japanese pharmaceutical companies to prompt developing new medicines. However, since the Ministry had to go on board with the healthcare expenditure, they are now pushing forward the generic drugs and medicine agenda.
How will Japanese pharmaceutical companies overcome this '2010 Problem'? How will the generic companies find ways for market expansion? The Interphex Japan and Int'l Bio Forum & Bio Expo Japan will be a good platform to know more about the issue.
In the Keynote Session on 'Future Prospects of the Japanese Pharmaceutical Industry and Tips for Further Development', top honchos of Japan's top pharmaceutical companies, Astellas Pharma's president & CEO, Masafumi Nogimori, and Bayer Yakuhin's chairman Norikazu Eiki, will deliver speeches on the pharmaceutical industry reorganization due to the emerging of generic drugs, along with manufactured product strategies and global strategies of Japanese pharmaceutical industry.
In the Special Session 5 [Int'l Bio Forum & Bio Expo Japan] on 'A Sea Change in Pharmaceutical R&D --Open Innovation in the Life Sciences', former senior director of Pfizer, Preston and President of NovaQuest will make a speech on the possibilities and the risks of developing new drugs. As drug discovery plays an important role on the development of economy of the country, the two will also refer on the new business model and approach methodology.
Organised by Reed Exhibitions Japan Ltd, Interphex Japan is the Asia's largest pharmaceutical exhibition, gathering various pharma service sectors, including pharma machineries, chemical ingredients and bio related products.